Diabetes complications

Reamputation risk and mortality after lower-limb amputation in patients with diabetes: predictors, effects of antidiabetic medications and temporal trends

Cardiovasc DiabetolPublished Observational longitudinal cohort study

Main findingResult — go to the resultHazard ratio 1.28 95% CI 1.08–1.52

Authors' conclusion

Diabetes remains to be associated with reduced reamputation-free survival; an association that is independent of increased prevalence of comorbidities in our data. Although reamputation risk has increased in recent years, overall survival has improved in patients with diabetes. Metformin usage is associated with improved reamputation-free survival while our limited data suggest increased risk of reamputation but safety with respect to mortality in patients treated with SGLT2i. Further studies are warranted to evaluate the effect of SGLT2i therapy on outcome in patients undergoing LLA.

Study context

Population
Patients undergoing non-traumatic lower limb amputation (LLA), 2006–2022
Participants
607 vs 500
Exposure
Diabetes vs no diabetes
  • Diabetesn = 607
  • No diabetesn = 500reference
Outcome
Reamputation-free survival
Methodological detailsCox regression, joint frailty models
  • Cox regression
  • Joint frailty models

Main finding

As reported in the abstract

Hazard ratio

1.28

95% CI 1.08–1.52

P = 0.004

Diabetesvs No diabetes
HR 1.28 (95% CI 1.08–1.52); P = 0.004

Observational data: associations, not effects.

Further findings

Metformin use in T2D: combined reamputation and mortality risk

HR (95% CI)P value
Metformin0.59 (0.43–0.81)P = 0.001

SGLT2i use: reamputation risk

HR (95% CI)P value
SGLT2i2.00 (1.47–2.72)P > 0.001

Predictors of reamputation-free survival / reamputation in diabetes

Higher HbA1c associated with lower reamputation-free survival
Older age, AF and CKD associated with increased reamputation risk

SGLT2i use: reamputation risk

SGLT2i use was low overall; safe with respect to mortality

Temporal trends in diabetes

Reamputation risk peaked in 2020–2022; mortality declined vs 2006–2010

Original publication

Reamputation risk and mortality after lower-limb amputation in patients with diabetes: predictors, effects of antidiabetic medications and temporal trends. Cardiovasc Diabetol. Published 23 March 2026. doi:10.1186/s12933-026-03145-9

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.